Zenex-VievePharm: The Indo-Dutch Play for the Post-Antibiotic Dairy Era

Zenex Animal Health, a dominant force in India’s veterinary sector, has formalised its acquisition of Netherlands-based VievePharm, an animal nutrition specialist headquartered in Enter. The transaction, advised by Investec, creates a cross-border powerhouse with over €100 million in revenue, positioned to lead the global shift toward sustainable, non-antibiotic livestock health.

This strategic integration marks a watershed moment for the Indian animal health industry. By absorbing VievePharm’s high-precision manufacturing capabilities and EU-certified facility, Zenex is no longer just a regional leader; it is a global contender in the preventive nutrition market. VievePharm, founded in 2006, brings a specialised portfolio of phytogenic formulations and advanced bolus technology that directly addresses the European Union’s urgent mandate to reduce veterinary antibiotic use.

Precision Delivery: The Bolus Advantage

The technical cornerstone of this acquisition is VievePharm’s bolus technology. Unlike traditional powders or liquid supplements that require daily administration, a bolus is a high-density, controlled-release delivery system that sits in the animal’s rumen.

• For the Dairy Farmer: It ensures a steady release of minerals, vitamins, and anti-inflammatory compounds over weeks or months, drastically reducing labour costs and animal handling stress.
• For Udder Health: Precision delivery of phytogenics through boluses offers a non-residue alternative to prophylactic antibiotics, specifically targeting mastitis—the single largest cause of milk loss globally.

Strategic Context: The ‘Farm to Fork’ Catalyst

The acquisition is perfectly timed to exploit the EU’s Farm to Fork Strategy, which mandates a 50% reduction in veterinary antibiotic sales by 2030. This regulatory squeeze has created a vacuum for science-backed “naturals.” Zenex is positioning itself as the primary provider for this transition, using VievePharm’s distribution network—spanning 25 countries—to introduce Indian-developed Ayurvedic and synthetic therapeutics into the European heartland.

The India Angle: Bridging the Productivity Gap

While the immediate focus is the EU market, the long-term benefit for the Indian dairy sector is profound. India’s bovine healthcare market, valued at ₹92.62 billion in 2025, is hampered by fragmented herd management.

• Tech Transfer: Zenex plans to deploy VievePharm’s bolus manufacturing expertise in India to address chronic mineral deficiencies in the domestic herd, which currently produces significantly less milk per animal than European counterparts.
• Standardisation: The acquisition brings Dutch quality-assurance standards (GMP+, FSA, and Skal) to the Zenex supply chain, essential for Indian dairy exporters aiming to supply the discerning EU and Middle Eastern markets.

Implications for Processors and Investors

For global dairy processors like Nestlé or Danone, Zenex’s expansion provides a reliable, non-chemical partner to meet corporate ESG and sustainability targets. For investors, the deal highlights a shift in the animal health M&A landscape: value is moving away from generic pharmaceuticals and toward specialised delivery systems and bio-active compounds.

Strategic Takeaway

The Zenex-VievePharm merger represents the “industrialisation of tradition.” By wrapping Indian Ayurvedic wisdom in European precision bolus technology, Zenex is creating a new category of “Naturals 2.0.” We expect other Indian majors to follow suit, targeting European R&D hubs to validate their herbal portfolios against Western clinical standards before the 2030 antibiotic deadline.